By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ignyta 

11095 Flintkote Avenue
Suite D
San Diego  California  92121  U.S.A.
Phone: Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Colorectal Cancer 2/17/2015 11:08:23 AM
Ignyta (RXDX) To Present At 2015 Leerink Global Healthcare Conference 2/5/2015 11:14:39 AM
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Non-Small Cell Lung Cancer 2/5/2015 9:35:26 AM
Ignyta (RXDX) Expands Clinical Leadership Team With Appointments Of Pratik Multani, M.D., M.S., As Chief Medical Officer And Adrian Senderowicz, M.D., As Clinical And Regulatory Strategy Officer 2/2/2015 11:18:25 AM
Ignyta (RXDX) To Participate In Life Sciences Panel Discussions With Other Thought Leaders At The 2015 East/West CEO Conference 1/6/2015 11:39:04 AM
Ignyta (RXDX) Receives Orphan Drug Designation And Rare Pediatric Disease Designation From FDA For Entrectinib For The Treatment Of Neuroblastoma 12/29/2014 9:01:51 AM
Ignyta (RXDX) Announces Amendment To License Agreement With Nerviano Medical Sciences (NervianoMS) 12/15/2014 10:14:02 AM
Ignyta (RXDX) Receives Approval Of Nonproprietary Name Entrectinib For Lead Product Candidate, RXDX-101 12/9/2014 1:19:30 PM
Ignyta (RXDX) Announces CLIA Certification Achieved By Its Diagnostic Laboratory 12/2/2014 3:12:01 PM
Ignyta (RXDX) To Present At Upcoming Investor Conferences 11/25/2014 1:59:26 PM
12345
//-->